Lung Cancer Screening: The European Perspective

Thoracic Surgery Clinics

Volumn 25, Issue 2, 2015, Pages 161-174

  Veronesi, Giulia ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Computed tomography; Diagnostic algorithm; Early stage lung cancer; Lung cancer; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ANNEXIN; BUDESONIDE; MICRORNA; NY ESO 1 ANTIGEN; PLACEBO; PROTEIN P53; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LOW DRUG DOSE; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; LUNG RESECTION; LYMPH NODE DISSECTION; NON SMALL CELL LUNG CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ROBOT ASSISTED SURGERY; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; STEREOTACTIC BODY RADIATION THERAPY; VIDEO ASSISTED THORACOSCOPIC SURGERY; ADVERSE EFFECTS; AGED; BLOOD; EUROPE; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE; RADIATION DOSE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING;

AGED; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; EUROPE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUALITY OF LIFE; RADIATION DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SOLITARY PULMONARY NODULE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84940923673     PISSN: None     EISSN: 15585069     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2014.12.002     Document Type: Review

References (55)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. NCI: SEER Cancer Statistics Review, 1996-2002.
3. Diederich S., Thomas M., Semik M., et al. Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol 2004, 14(4):691.
4. Henschke C.I., McCauley D.I., Yankelevitz D.F., et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354(9173):99.
5. Sone S., Li F., Yang Z.G., et al. Characteristics of small lung cancers invisible on conventional chest radiography and detected by population based screening using spiral CT. Br J Radiol 2000, 73(866):137.
6. Aberle D.R., Adams A.M., Berg C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365(5):395-409.
7. McMahon P.M., Kong C.Y., Johnson B.E., et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT Screening Study. Radiology 2008, 248:278-287.
8. Chien C.R., His T.H. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. Int J Cancer 2008, 122:2594-2599.
9. American Society of Clinical Oncology. The Role of CT Screening for Lung Cancer in Clinical Practice. The Evidence Based Practice Guideline of the American College of Chest Physicians and the American Society for Clinical Oncology. Available at: . Accessed January 23, 2014. May 20, 2012. http://www.asco.org/quality-guidelines/role-ct-screening-lung-cancer-clinical-practice-evidencebased-practice-guideline.
10. Humphrey L.L., Deffebach M., Pappas M., et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2013, 159:411-420.
11. Boeri M., Verri C., Conte D., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713-3718.
12. Bianchi F., Hu J., Pelosi G., et al. Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analyzed by cDNA microarray. Clin Cancer Res 2004, 10(18 Pt 1):6023-6028.
13. Field J.K., Oudkerk M., Pedersen J.H., et al. Prospects for population screening and diagnosis of lung cancer. Lancet 2013, 382(9893):732-741.
14. Centers for Disease Control and Prevention. Lung cancer: risk factors. Available at: . Accessed July 1, 2013. http://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm.
15. US Department of Health and Human Services, Centers for Disease Control and Prevention and Health Promotion, Office on Smoking and Health The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General 2014, 4-20. USDHSS, Washington, DC.
16. Ashraf H., Tønnesen P., Holst Pedersen J., et al. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). Thorax 2009, 64:388-392.
17. van der Aalst C.M., van den Bergh K.A., Willemsen M.C., et al. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010, 65(7):600-605.
18. van der Aalst C.M., de Koning H.J., van den Bergh K.A., et al. The effectiveness of a computer-tailored smoking cessation intervention for participants in lung cancer screening: a randomised controlled trial. Lung Cancer 2012, 76(2):204-210.
19. Keith R.L., Miller Y.E. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 2013, 10:334-343.
20. Veronesi G., Szabo E., Decensi A., et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) 2011, 4:34-42.
21. Rothwell P.M., Fowkes F.G., Belch J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
22. Cuzick J., Thorat M.A., Bosetti C., et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2014.
23. Veronesi G., Maisonneuve P., Spaggiari L., et al. Diagnostic performance of low-dose computed tomography screening for lung cancer over five years. J Thorac Oncol 2014, 9(7):935-939.
24. International Early Lung Cancer Action Program Investigators Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355(17):1763-1771.
25. Available at: . Accessed July 1, 2013. http://seer.cancer.gov/statfacts/html/lungb.html.
26. van Klaveren R.J., Oudkerk M., Prokop M., et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009, 361(23):2221-2229.
27. Nair A., Hansell D.M. European and North American lung cancer screening experience and implications for pulmonary nodule management. Eur Radiol 2011, 21(12):2445-2454.
28. Baldwin D.R., Duffy S.W., Wald N.J., et al. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011, 66(4):308-313.
29. Veronesi G., Bellomi M., Veronesi U., et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 2007, 84:959-965.
30. Veronesi G., Travaini L.L., Maisonneuve P., et al. Positron emission tomography in the diagnostic work-up of screening-detected lung nodules. Eur Respir J 2014, [Epub ahead of print].
31. Ashraf H., Dirksen A., Loft A., et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011, 66:315-319.
32. Infante M., Cavuto S., Lutman F.R., et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 2009, 180(5):445-453.
33. Pastorino U., Rossi M., Rosato V., et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012, 21(3):308-315.
34. Saghir Z., Dirksen A., Ashraf H., et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose. Thorax 2012, 67(4):296-301.
35. Veronesi G., Maisonneuve P., Spaggiari L., et al. Long-term outcomes of a pilot CT screening for lung cancer. Ecancermedicalscience 2010, 4:186.
36. Veronesi G., Maisonneuve P., Bellomi M., et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer a cohort study. Ann Intern Med 2012, 157(11):776-784.
37. Nakamura K., Saji H., Nakajima R., et al. Phase III randomised trial of lobectomy versus limited resection for small size peripheral NSCLC (JCOG0802/WJOG4607L). Jpn J Clin Oncol 2010, 40:271-274.
38. Guckenberger M., Allgäuer M., Appold S., et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 2013, 8(8):1050-1058.
39. Robinson C.G., DeWees T.A., El Naqa I.M., et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol 2013, 8:192-201.
40. Petersen R.H., Hansen H.J., Dirksen A., et al. Lung cancer screening and video-assisted thoracic surgery. J Thorac Oncol 2012, 7(6):1026-1031.
41. Veronesi G., Galetta D., Maisonneuve P., et al. Four-arm robotic lobectomy for the treatment of early-stage lung cancer. J Thorac Cardiovasc Surg 2010, 140(1):19-25.
42. Veronesi G., Maisonneuve P., Pelosi G., et al. Screening-detected lung cancers: is systematic nodal dissection always essential?. J Thorac Oncol 2011, 6(3):525-530.
43. Casiraghi M., Travaini L.L., Maisonneuve P., et al. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?. Eur J Cardiothorac Surg 2011, 39(4):e38-e43.
44. Senan S., Paul M.A., Lagerwaard F.J. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?. Lancet Oncol 2013, 14(7):e270-e274.
45. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366-377.
46. Shen J., Todd N.W., Zhang H., et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011, 91:579-587.
47. Zheng D., Haddadin S., Wang Y., et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011, 4:575-586.
48. Bianchi F., Nicassio F., Marzi M., et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011, 3:495-503.
49. Chen X., Ba Y., Ma L. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
50. Valadi H., Ekström K., Bossios A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9(6):654-659.
51. Cassidy A., Myles J.P., van Tongeren M., et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008, 98:270-276.
52. Maisonneuve P., Bagnardi V., Bellomi M., et al. Lung Cancer Risk Prediction to Select Smokers for Screening CT-a Model Based on the Italian COSMOS Trial. Cancer Prev Res (Phila) 2011, 4(11):1778-1789.
53. Bach P.B., Kattan M.W., Thornquist M.D., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003, 95:470-478.
54. Gnagnarella P., Maisonneuve P., Bellomi M., et al. Red meat, Mediterranean diet and lung cancer risk among heavy smokers in the COSMOS screening study. Ann Oncol 2013, 24(10):2606-2611.
55. Slimani N., Deharveng G., Charrondiere R.U., et al. Structure of the standardized computerized 24-h diet recall interview used as reference method in the 22 centers participating in the EPIC project. European Prospective Investigation into Cancer and Nutrition. Comput Methods Programs Biomed 1999, 58:251-266.